Chengdu Easton Biopharmaceuticals (688513.SH) announced on September 2nd that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd. (referred to as "Shuode Pharmaceutical"), recently received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration. The main component of the fluoxetine maleate tablets is fluoxetine maleate, and it is indicated for: (1) depression; (2) obsessive-compulsive disorder.
苑东生物(688513.SH)：马来酸氟伏沙明片获得药品注册证书
chengdu easton biopharmaceuticals (688513.SH): The registration certificate of fluvoxamine maleate tablets for pharmaceutical has been obtained
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.